Cinoxacin, a synthetic organic acid antibacterial agent, related structurally to nalidixic and oxolinic acid, has been approved for the treatment of initial and recurrent urinary tract infections (UTIs) caused by susceptible gram-negative microorganisms. The role of cinoxacin in the treatment of UTIs, compared with the usual first-line agents, is uncertain at this time. The efficacy of cinoxacin in the treatment of pyelonephritis, compared with these proven agents, has been examined in only small numbers of patients, and cinoxacin is more expensive than these agents. Cinoxacin may prove valuable in the treatment of prostatitis and in the prophylaxis of recurrent UTIs; further study in these areas is warranted. In the routine treatment of acute UTIs, cinoxacin perhaps should be reserved only for those patients with organisms resistant to usual first-line agents or those who fail to respond to therapy with these agents. In this respect, cinoxacin may, in the future, replace nalidixic acid.
Lilly Research Laboratories.Clinical pharmacology of cinoxacin. Information for clinical investigators. Indianapolis: Eli Lilly, 1980.
2.
GiamarellouHJacksonGG. Antibacterial activity of cinoxacin in vitro. Antimicrob Agents Chemother1975; 7: 688–92.
3.
StaudenbauerWL. Replication of Escherichia coli DNA in vitro: Inhibition by oxolinic acid. Eur J Biochem1976; 62: 491–7.
4.
GrossWADeitzWHCookTM. Mechanism of action of nalidixic acid on Escherichia coli, part II, inhibition of deoxyribonucleic acid synthesis. J Bacteriol1965; 89: 1068–74.
5.
CrumplingGCSmithJT. Nalidixic acid and bacterial chromosomal replication. Nature1976; 260: 643–5.
6.
PianottiRSMohanRRSchwartzBS. Biochemical effects of oxolinic acid on Proteus vulgaris. J Bacteriol1968; 95: 1622–8.
7.
MardhPAArhammerMColleenSAnderssonKE. Microcalorimetric investigation of the action of cinoxacin against Escherichia coli. J Antimicrob Chemother1978; 4: 73–8.
8.
KurtzSTurckM.In vitro activity of cinoxacin, an organic acid antibacterial. Antimicrob Agents Chemother1975; 7: 370–3.
9.
LumishRMNordenCW. Cinoxacin: In vitro antibacterial studies of a new synthetic organic acid. Antimicrob Agents Chemother1975; 7: 159–63.
10.
BarnhamMGayaH.In vitro susceptibility of urinary isolates of Escherichia coli to cinoxacin. J Antimicrob Chemother1979; 5: 413–8.
11.
RubinsteinEShainbergB.In vitro activity of cinoxacin, ampicillin and chloramphenicol against shigella and nontyphoid salmonella. Antimicrob Agents Chemother1977; 11: 577–9.
12.
WickWEPrestonDAWhiteWAGordieRS. Compound 64716, a new synthetic antibacterial agent. Antimicrob Agents Chemother1973; 4: 415–20.
13.
MardhPAColleenSAnderssonKE. Studies on cinoxacin. 1. In vitro activity of cinoxacin, as compared to nalidixic acid, against urinary tract pathogens. J Antimicrob Chemother1977; 3: 411–6.
14.
JonesRNFuchsPC. In vitro antimicrobial activity of cinoxacin against 2968 clinical bacterial isolates. Antimicrob Agents Chemother1976; 10: 146–9.
15.
GordonRCStevensLIEdmistonCEJrMohanK.Comparative in vitro studies of cinoxacin, nalidixic acid, and oxolinic acid. Antimicrob Agents Chemother1976; 10: 918–20.
16.
BlackHRIsraelKSWolenRL, Pharmacology of cinoxacin in humans. Antimicrob Agents Chemother1979; 15: 165–70.
17.
ColleenSAnderssonKEMardhPA. Studies on cinoxacin. 3. Concentrations of cinoxacin in serum, urine, and tissues of urological patients. J Antimicrob Chemother1977; 3: 579–84.
18.
MaigaardSFrimodt-MollerNWellingPGMadsenPO. Cinoxacin: Pharmacokinetics and tolerance in patients with normal and impaired renal function. Antimicrob Agents Chemother1979; 16: 411–6.
19.
BurtRAPMorganTPayneJPBonnerRM. Cinoxacin concentrations in plasma, urine, and prostatic tissue after oral administration to man. Br J Urol1977; 49: 147–52.
20.
PanwalkerAPGiamarellouHJacksonGG. Efficacy of cinoxacin in urinary tract infections. Antimicrob Agents Chemother1976; 9: 502–5.
21.
IsraelKSBlackHRNelsonRL, Cinoxacin: Pharmacokinetics and the effect of probenecid. J Clin Pharmacol1978; 18: 491–9.
22.
RodriguezNMadsenPOWellingPG. Influence of probenecid on serum levels and urinary excretion of cinoxacin. Antimicrob Agents Chemother1979; 15: 465–9.
23.
WolenRLObermeyerBDZeigeEABlackHR. Metabolic fate of cinoxacin (1-ethyl-1,4-dihydro-4-oxo-(1,3)-dioxolo-(4,5-g)-cinnoline-3-carboxylic acid) in man (abstract). Clin Pharmacol Ther1976; 19: 119.
24.
SzwedJJBrannonDESloanRSLuftFC. Pharmacokinetics of cinoxacin in patients with renal failure. J Antimicrob Chemother1978; 4: 451–4.
25.
AffrimeMBLowenthalDTSchwartzAShirkJSamuelsAOnestiG.The pharmacokinetics of cinoxacin in varying degrees of renal function (abstract). Clin Pharmacol Ther1980; 27: 243.
26.
BlanfordMFViscontiJAGrauerDWBayWH. The pharmacokinetics of cinoxacin after multiple dosing in patients with renal insufficiency (abstract). Drug Intell Clin Pharm1980; 14: 632.
27.
BennettAH. The use of cinoxacin in urinary tract infections. In: WilliamsJDGeddesAM, eds. Chemotherapy, volume 5: Penicillins and cephalosporins. New York:Plenum Press, 1975: 417–8.
28.
LandesRRHallJW. Cinoxacin: New antimicrobial agent for urinary tract infections. Urology1977; 10: 312–6.
29.
LandesRR. Long-term low dose cinoxacin therapy for the prevention of recurrent urinary tract infections. J Urol1980; 123: 47–50.
30.
RousSN. Cinoxacin in the treatment of acute urinary tract infections: An evaluation of efficacy and a comparison of dosage schedules. J Urol1978; 120: 196–7.
31.
WellesJSIsraelKSBlackHR. Multicentre clinical evaluation of cinoxacin in urinary tract infections. In: SiegenthalerWLuthyR, eds. Current chemotherapy, volume 2. Washington, DC: American Society for Microbiology, 1978: 1041–2.
32.
SantosMLlopisBCisnalJMRomanJGobernadoM.Cinoxacin in the treatment of chronic urinary tract infections. In: SiegenthalerWLuthyR, eds. Current chemotherapy, volume 1. Washington, DC: American Society for Microbiology, 1978: 696–7.
33.
ExaireE.Cinoxacin therapy of urinary tract infections. In: SiegenthalerWLuthyR, eds. Current chemotherapy, volume 1. Washington, DC: American Society for Microbiology, 1978: 697–8.
34.
JonesGWMulhollandSG. Treatment of outpatient urinary tract infections with cinoxacin. J Fam Pract1980; 11: 207–10.
35.
EloJTallgrenLGSarnaS.Treatment of childhood urinary tract infection with cinoxacin. In: SiegenthalerWLuthyR, eds. Current chemotherapy, volume 1. Washington, DC: American Society for Microbiology, 1978: 693–5.
36.
CoxCESimmonsJR. Cinoxacin in therapy of urinary tract infections. Comparison of two dosage regimens. Urology1981; 17: 539–41.
37.
DrylieDM. Comparison of cinoxacin and nalidixic acid in the treatment of urinary tract infections. In: SiegenthalerWLuthyR, eds. Current chemotherapy, volume 1. Washington, DC: American Society for Microbiology, 1978: 700–2.
38.
WilsonP.Comparative trial of cinoxacin and nalidixic acid in urinary tract infection. In: SiegenthalerWLuthyR, eds. Current chemotherapy, volume 1. Washington, DC: American Society for Microbiology, 1978: 699–700.
39.
BucyJG. A clinical comparison of cinoxacin and nalidixic acid in the treatment of urinary tract infection. J Urol1981; 125: 822–4.
40.
KlasterskyJKahan-CoppensL.Comparative study of cinoxacin and co-trimoxazole in complicated urinary tract infections: A double-blind randomized study. In: SiegenthalerWLuthyR, eds. Current chemotherapy, volume 1. Washington, DC: American Society for Microbiology, 1978: 702–4.
41.
SchaefferAJFlynnSJonesJ.Comparison of cinoxacin and trimethoprim-sulfamethoxazole in the treatment of urinary tract infections. J Urol1981; 125: 825–7.
42.
LindanR.Comparison of cinoxacin and nitrofurantoin in the treatment of urinary tract infections in geriatric patients. In: SiegenthalerWLuthyR, eds. Current chemotherapy, volume 1. Washington, DC: American Society for Microbiology, 1978: 704–5.
43.
LandesRR. Cinoxacin for treatment and prevention of recurrent urinary tract infection. Urology1981; 17: 505–10.
44.
RonaldRRTurckMPetersdorfRG. A critical evaluation of nalidixic acid in urinary tract infections. N Engl J Med1966; 275: 1081–9.
45.
StameyTABragonjeJ.Resistance to nalidixic acid: A misconception due to underdosage. JAMA1976; 236: 1857–60.
46.
CederbergADennebergTEkbergM, Nalidixic acid in urinary tract infections with particular reference to the emergence of resistance. Scand J Infect Dis1974; 6: 259–64.
GleckmanRAlvarezSJoubertDWMatthewsSJ. Drug therapy reviews: Nalidixic acid. Am J Hosp Pharm1979; 36: 1071–6.
49.
GleckmanRAlvarezSJoubertDWMatthewsSJ. Drug therapy reviews: Oxolinic acid. Am J Hosp Pharm1979; 36: 1077–9.
50.
QuayJFChildersRFJohnsonDWNashJFStuckyJFIICinoxacin in female mongrel dogs. Effect of urine pH on urinary drug excretion and correlation of in vitro characteristics of oral dosage forms with bioavailability. J Pharm Sci1979; 68: 227–31.
